Dechra sees slowdown of growth in European sector

Dechra Pharmaceuticals said in a trading statement Tuesday that its first half has been in line with management expectations, but admitted its European Pharmaceuticals segment saw growth slow from 73.7 per cent to 61.4 per cent year-on-year.

Dechra Pharmaceuticals said in a trading statement Tuesday that its first half has been in line with management expectations, but admitted its European Pharmaceuticals segment saw growth slow from 73.7 per cent to 61.4 per cent year-on-year.

The reported divisional performance over the corresponding period last year, excluding Eurovet Animal Health, declined by 2.4% (an increase of 4.5% at constant currency), which the group said reflected an exceptional increase last year of £1.2m in the production of Vetoryl for the US market to ensure continuity of supply as it implemented manufacturing changes.

Planned changes to distribution arrangements in France and Germany also had an adverse effect on reported revenue, the firm said.

More positively, the integration of Eurovet continued to progress well and is delivering expected cost and revenue synergies.

In US Pharmaceuticals, revenue was ahead of the corresponding period last year by 10.0% (10.4% at constant currency), with strong growth seen in its DermaPet, Vetoryl and Felimazole products.

Revenues from the services division rose 5.1% compared to the prior year, while operating margin over the 12 months "demonstrated a modest improvement over the corresponding period last year".

The group commented that it made a "strong start to the financial year which is in line with the board's expectations".

The share price fell 2.8% to 625p on Tuesday morning.

NR

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Here’s why you really should own at least some bitcoin
Bitcoin

Here’s why you really should own at least some bitcoin

While bitcoin is having a quiet year – at least in relative terms – its potential to become the default cash system for the internet is undiminished, …
16 Sep 2020
Central banks want politicians to take charge – but what will they do?
US Economy

Central banks want politicians to take charge – but what will they do?

The US Federal Reserve has come to the end of the road in terms of what it can do to accelerate any recovery, says John Stepek. It's over to the polit…
17 Sep 2020
IAG's share price is ready for take-off - here's how to play it
Trading

IAG's share price is ready for take-off - here's how to play it

The owner of British Airways has had a turbulent year, but is now worth a punt. Matthew Partridge explains the best way to play it.
8 Sep 2020